Updated
Merck research facility in San Francisco
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
ABOVE: ISTOCK JASONDOIY
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death

Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.

Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.

ABOVE: ISTOCK JASONDOIY
capsule
Cellular capsules deliver drugs
Megan Scudellari | Jun 20, 2011
Drug capsules manufactured by living cells help drugs evade immune attack.